Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 3Burkitt Lymphoma 3Neuroblastoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Leukemia 2Ganglioneuroblastoma 2Smoldering Multiple Myeloma 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myelomonocytic, Juvenile 1Immunoglobulin Light-chain Amyloidosis 1Hemoglobinuria, Paroxysmal 1Hemoglobinuria 1Breast Neoplasms 1

Interventions

Dexamethasone 20Melphalan 13Thalidomide 10Bortezomib 10Lenalidomide 8Cyclophosphamide 8Prednisone 6Filgrastim 6Doxorubicin 6Vincristine 5Epoetin Alfa 5pomalidomide 3Zoledronic Acid 3Peripheral Blood Stem Cell Transplantation 3Idarubicin 3carfilzomib 2Vorinostat 2Radiotherapy 2Interferon-alpha 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Darbepoetin alfa 2Carmustine 2Calcium Dobesilate 2Busulfan 2valspodar 1sargramostim 1oblimersen 1liposomal doxorubicin 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Plasma Cell × Stem Cell Transplantation × Clear all
NCT01413178 2020-04-21

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

M.D. Anderson Cancer Center

Phase 3 Completed
205 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡